1. Sinclair J, Reeves M. The intimate relationship between human cytomegalovirus and the dendritic cell lineage. Front Microbiol. 2014; 5:389.
Article
2. Weller TH. The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. N Engl J Med. 1971; 285:203–214.
Article
3. Landolfo S, Gariglio M, Gribaudo G, Lembo D. The human cytomegalovirus. Pharmacol Ther. 2003; 98:269–297.
Article
4. Hassan J, Connell J. Translational Mini-Review Series on Infectious Disease: Congenital cytomegalovirus infection: 50 years on. Clin Exp Immunol. 2007; 149:205–210.
Article
5. Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest. 2011; 121:1673–1680.
Article
6. Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis. 2006; 43:1143–1151.
Article
7. Jesionek A, Kiolemenoglou B. Ueber einen befund von protozoenartigen gebilden in den organen eines hereditar-luetis-chen foetus. Muenchner Med Wochenschr. 1904; 51:1905–1907.
8. Smith MG. Propagation in tissue cultures of a cytopathogenic virus from human salivary gland virus (SGV) disease. Proc Soc Exp Biol Med. 1956; 92:424–430.
Article
9. Craig JM, Macauley JC, Weller TH, Wirth P. Isolation of intranuclear inclusion producing agents from infants with illnesses resembling cytomegalic inclusion disease. Proc Soc Exp Biol Med. 1957; 94:4–12.
Article
10. Elek SD, Stern H. Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet. 1974; 1:1–5.
Article
11. Plotkin SA, Furukawa T, Zygraich , Huygelen C. Candidate cytomegalovirus strain for human vaccination. Infect Immun. 1975; 12:521–527.
Article
12. Just M, Buergin-Wolff A, Emoedi G, Hernandez R. Immunisation trials with live attenuated cytomegalovirus TOWNE 125. Infection. 1975; 3:111–114.
Article
13. Brayman KL, Dafoe DC, Smythe WR, Barker CF, Perloff LJ, Naji A, et al. Prophylaxis of serious cytomegalovirus infection in renal transplant candidates using live human cytomegalovirus vaccine. Interim results of a randomized controlled trial. Arch Surg. 1988; 123:1502–1508.
Article
14. Khanna R, Diamond DJ. Human cytomegalovirus vaccine: time to look for alternative options. Trends Mol Med. 2006; 12:26–33.
Article
15. Krause PR, Bialek SR, Boppana SB, Griffiths PD, Laughlin CA, Ljungman P, et al. Priorities for CMV vaccine development. Vaccine. 2013; 32:4–10.
Article
16. Chee MS, Bankier AT, Beck S, Bohni R, Brown CM, Cerny R, et al. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr Top Microbiol Immunol. 1990; 154:125–169.
Article
17. Dargan DJ, Douglas E, Cunningham C, Jamieson F, Stanton RJ, Baluchova K, et al. Sequential mutations associated with adaptation of human cytomegalovirus to growth in cell culture. J Gen Virol. 2010; 91:1535–1546.
Article
18. Renzette N, Gibson L, Bhattacharjee B, Fisher D, Schleiss MR, Jensen JD, et al. Rapid intrahost evolution of human cytomegalovirus is shaped by demography and positive selection. PLoS Genet. 2013; 9:e1003735.
Article
19. Fernández-Ruiz M, Corrales I, Arias M, Campistol JM, Giménez E, Crespo J, et al. Association between individual and combined SNPs in genes related to innate immunity and incidence of CMV infection in seropositive kidney transplant recipients. Am J Transplant. 2015; 15:1323–1335.
Article
20. Murphy E, Yu D, Grimwood J, Schmutz J, Dickson M, Jarvis MA, et al. Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc Natl Acad Sci U S A. 2003; 100:14976–14981.
Article
21. Novak Z, Ross SA, Patro RK, Pati SK, Kumbla RA, Brice S, et al. Cytomegalovirus strain diversity in seropositive women. J Clin Microbiol. 2008; 46:882–886.
Article
22. Renzette N, Pokalyuk C, Gibson L, Bhattacharjee B, Schleiss MR, Hamprecht K, et al. Limits and patterns of cytomegalovirus genomic diversity in humans. Proc Natl Acad Sci U S A. 2015; 112:E4120–E4128.
Article
23. Lee GC, Lee DG, Choi SM, Yoo JH, Park SH, Choi JH, et al. Use of Time-Saving Flow Cytometry for Rapid Determination of Resistance of Human Cytomegalovirus to Ganciclovir. J Clin Microbiol. 2005; 43:5003–5008.
Article
24. Jung GS, Kim YY, Kim JI, Ji GY, Jeon JS, Yoon HW, et al. Full genome sequencing and analysis of human cytomegalovirus strain JHC isolated from a Korean patient. Virus Res. 2011; 156:113–120.
Article
25. Davison AJ, Akter P, Cunningham C, Dolan A, Addison C, Dargan DJ, et al. Homology between the human cytomegalovirus RL11 gene family and human adenovirus E3 genes. J Gen Virol. 2003; 84:657–663.
Article
26. Cunningham C, Gatherer D, Hilfrich B, Baluchova K, Dargan DJ, Thomson M, et al. Sequences of complete human cytomegalovirus genomes from infected cell cultures and clinical specimens. J Gen Virol. 2010; 91:605–615.
Article
27. Wilkinson GW, Davison AJ, Tomasec P, Fielding CA, Aicheler R, Murrell I, et al. Human cytomegalovirus: taking the strain. Med Microbiol Immunol. 2015; 204:273–284.
Article
28. Sijmons S, Thys K, Mbong Ngwese M, Van Damme E, Dvorak J, Van Loock M, et al. High-throughput analysis of human cytomegalovirus genome diversity highlights the widespread occurrence of gene-disrupting mutations and pervasive recombination. J Virol. 2015; 89:7673–7695.
Article
29. Dunn W, Chou C, Li H, Hai R, Patterson D, Stolc V, et al. Functional profiling of a human cytomegalovirus genome. Proc Natl Acad Sci U S A. 2003; 100:14223–14228.
Article
30. Bruno L, Cortese M, Monda G, Gentile M, Caló S, Schiavetti F, et al. Human cytomegalovirus pUL10 interacts with leukocytes and impair TCR mediated T-cell activation. Immunol Cell Biol. 2016; 94:849–860.
Article